

Dear Author,

Here are the proofs of your article.

- You can submit your corrections **online**, via **e-mail** or by **fax**.
- For **online** submission please insert your corrections in the online correction form. Always indicate the line number to which the correction refers.
- You can also insert your corrections in the proof PDF and **email** the annotated PDF.
- For fax submission, please ensure that your corrections are clearly legible. Use a fine black pen and write the correction in the margin, not too close to the edge of the page.
- Remember to note the **journal title**, **article number**, and **your name** when sending your response via e-mail or fax.
- **Check** the metadata sheet to make sure that the header information, especially author names and the corresponding affiliations are correctly shown.
- **Check** the questions that may have arisen during copy editing and insert your answers/ corrections.
- **Check** that the text is complete and that all figures, tables and their legends are included. Also check the accuracy of special characters, equations, and electronic supplementary material if applicable. If necessary refer to the *Edited manuscript*.
- The publication of inaccurate data such as dosages and units can have serious consequences. Please take particular care that all such details are correct.
- Please **do not** make changes that involve only matters of style. We have generally introduced forms that follow the journal's style. Substantial changes in content, e.g., new results, corrected values, title and authorship are not allowed without the approval of the responsible editor. In such a case, please contact the Editorial Office and return his/her consent together with the proof.
- If we do not receive your corrections **within 48 hours**, we will send you a reminder.
- Your article will be published **Online First** approximately one week after receipt of your corrected proofs. This is the **official first publication** citable with the DOI. **Further changes are, therefore, not possible.**
- The **printed version** will follow in a forthcoming issue.

Please note

After online publication, subscribers (personal/institutional) to this journal will have access to the complete article via the DOI using the URL: [http://dx.doi.org/\[DOI\]](http://dx.doi.org/[DOI]).

If you would like to know when your article has been published online, take advantage of our free alert service. For registration and further information go to: <http://www.link.springer.com>.

Due to the electronic nature of the procedure, the manuscript and the original figures will only be returned to you on special request. When you return your corrections, please inform us if you would like to have these documents returned.

Metadata of the article that will be visualized in OnlineFirst

Please note: Images will appear in color online but will be printed in black and white.

ArticleTitle	Effects of Aib residues insertion on the structural-functional properties of the frog skin-derived peptide Esculetin-1a(1–21)-NH ₂	
<hr/>		
Article Sub-Title		
Article CopyRight	Springer-Verlag Wien (This will be the copyright line in the final PDF)	
Journal Name	Amino Acids	
<hr/>		
Corresponding Author	Family Name	Mangoni
	Particle	
	Given Name	Maria Luisa
	Suffix	
	Division	Department of Biochemical Sciences, Istituto Pasteur-Fondazione Cenci Bolognetti
	Organization	Sapienza University of Rome
	Address	Via degli Apuli, 9, 00185, Rome, Italy
	Phone	+39 06 49917693
	Fax	
	Email	marialuisa.mangoni@uniroma1.it
	URL	
	ORCID	
<hr/>		
Author	Family Name	Biondi
	Particle	
	Given Name	Barbara
	Suffix	
	Division	Padova Unit, CNR
	Organization	Institute of Biomolecular Chemistry
	Address	Via Marzolo 1, 35131, Padova, Italy
	Phone	
	Fax	
	Email	
	URL	
	ORCID	
<hr/>		
Author	Family Name	Casciaro
	Particle	
	Given Name	Bruno
	Suffix	
	Division	Department of Biochemical Sciences, Istituto Pasteur-Fondazione Cenci Bolognetti
	Organization	Sapienza University of Rome
	Address	Via degli Apuli, 9, 00185, Rome, Italy
	Phone	

Fax
Email
URL
ORCID

Author	Family Name	Grazia
	Particle	Di
	Given Name	Antonio
	Suffix	
	Division	Department of Biochemical Sciences, Istituto Pasteur-Fondazione Cenci Bolognetti
	Organization	Sapienza University of Rome
	Address	Via degli Apuli, 9, 00185, Rome, Italy
	Phone	
	Fax	
	Email	
	URL	
	ORCID	

Author	Family Name	Cappiello
	Particle	
	Given Name	Floriana
	Suffix	
	Division	Department of Biochemical Sciences, Istituto Pasteur-Fondazione Cenci Bolognetti
	Organization	Sapienza University of Rome
	Address	Via degli Apuli, 9, 00185, Rome, Italy
	Phone	
	Fax	
	Email	
	URL	
	ORCID	

Author	Family Name	Luca
	Particle	
	Given Name	Vincenzo
	Suffix	
	Division	Department of Biochemical Sciences, Istituto Pasteur-Fondazione Cenci Bolognetti
	Organization	Sapienza University of Rome
	Address	Via degli Apuli, 9, 00185, Rome, Italy
	Phone	
	Fax	
	Email	
	URL	
	ORCID	

Author	Family Name	Crisma
	Particle	
	Given Name	Marco

Prefix
Division Padova Unit, CNR
Organization Institute of Biomolecular Chemistry
Address Via Marzolo 1, 35131, Padova, Italy
Phone
Fax
Email
URL
ORCID

	Received	2 August 2016
Schedule	Revised	
	Accepted	28 September 2016

Abstract Antimicrobial peptides (AMPs) play a key role in the defence mechanism of living organisms against microbial pathogens, displaying both bactericidal and immunomodulatory properties. They are considered as a promising alternative to the conventional antibiotics towards which bacteria are becoming highly resistant. Recently, a derivative of the frog skin AMP Esculetin-1a, Esculetin-1a(1–21)NH₂ [Esc(1–21)], showed a strong and fast membranolytic activity against Gram-negative bacteria but with a lower efficacy against Gram-positive ones. Here, with the aim to increase the α -helicity of Esc(1–21) and the expected potency against Gram-positive bacteria, we designed an analog bearing three α -aminoisobutyric acid (Aib) residues at positions 1, 10, and 18 of its primary structure. We demonstrated that the incorporation of Aib residues: (1) promoted the α -helix conformation of Esc(1–21), as confirmed by circular dichroism and two-dimensional nuclear magnetic resonance spectroscopies; (2) was sufficient to make this analog more active than the parent peptide against several Gram-positive bacterial strains without affecting its activity against Gram-negative bacteria; and (3) resulted to be devoid of toxic effect toward epithelial cells at the active antimicrobial concentrations. These results suggest that replacement of L-amino acids with Aib residues has beneficial effects on the structure and properties of the membrane-active peptide Esc(1–21), making it a better candidate for the design and development of selective drugs against Gram-positive bacteria.

Keywords (separated by '-') Antimicrobial peptides - α -Aminoisobutyric acid - Gram-positive bacteria - NMR

Footnote Information Handling Editor: M. S. Palma.

2 Effects of Aib residues insertion on the structural-functional 3 properties of the frog skin-derived peptide Esculentin-1a(1–21)-NH₂

4 Barbara Biondi¹ · Bruno Casciaro² · Antonio Di Grazia² · Floriana Cappiello² ·
5 Vincenzo Luca² · Marco Crisma¹ · Maria Luisa Mangoni²

6 Received: 2 August 2016 / Accepted: 28 September 2016
7 © Springer-Verlag Wien 2016

AQ1 **Abstract** Antimicrobial peptides (AMPs) play a key role in the defence mechanism of living organisms against microbial pathogens, displaying both bactericidal and immunomodulatory properties. They are considered as a promising alternative to the conventional antibiotics towards which bacteria are becoming highly resistant. Recently, a derivative of the frog skin AMP Esculentin-1a, Esculentin-1a(1–21)NH₂ [Esc(1–21)], showed a strong and fast membranolytic activity against Gram-negative bacteria but with a lower efficacy against Gram-positive ones. Here, with the aim to increase the α -helicity of Esc(1–21) and the expected potency against Gram-positive bacteria, we designed an analog bearing three α -aminoisobutyric acid (Aib) residues at positions 1, 10, and 18 of its primary structure. We demonstrated that the incorporation of Aib residues: (1) promoted the α -helix conformation of Esc(1–21), as confirmed by circular dichroism and two-dimensional nuclear magnetic resonance spectroscopies; (2) was sufficient to make this analog more active than the parent peptide against several Gram-positive bacterial strains without affecting its activity against Gram-negative bacteria; and (3) resulted to be devoid of toxic effect toward epithelial cells at the active antimicrobial concentrations. These results suggest that replacement of L-amino acids with Aib residues has beneficial effects on the structure and properties of the membrane-active peptide Esc(1–21),

making it a better candidate for the design and development of selective drugs against Gram-positive bacteria.

34
35

Keywords Antimicrobial peptides · α -Aminoisobutyric acid · Gram-positive bacteria · NMR

36
37

Abbreviations

CD	Circular dichroism	38
DIEA	<i>N,N</i> -Diisopropylethylamine	39
DMEM	Dulbecco's modified Eagle's medium	40
FBS	Heat-inactivated fetal bovine serum	41
HATU	1-[Bis(dimethylamino)methylene]-1 <i>H</i> -1,2,3-triazolo[4,5- <i>b</i>]pyridinium 3-oxide hexafluorophosphate	42
HBTU	<i>N,N,N',N'</i> -Tetramethyl- <i>O</i> -(1 <i>H</i> -benzotriazol-1-yl)uronium hexafluorophosphate	43
HOBt	1-Hydroxybenzotriazole	44
MBHA	4-Methylbenzhydrylamine	45
MH	Mueller–Hinton	46
MTT	3(4,5-Dimethylthiazol-2-yl)2,5-diphenyltetrazolium bromide	47
NMR	Nuclear magnetic resonance	48
SDS	Sodium dodecylsulfate	49
TFA	Trifluoroacetic acid	50
TFE	Trifluoroethanol	51

Introduction

57

Ribosomally made antimicrobial peptides (AMPs) are produced by all species of life throughout the evolutionary scale as principal components of their innate defence system against invading microorganisms (Gonzalez-Navajas et al. 2014; Mangoni and Shai 2011; Mookherjee and Hancock 2007; Nicolas and Mor 1995). Furthermore, they are endowed with immunomodulatory properties (Choi et al.

58
59
60
61
62
63
64

A1 Handling Editor: M. S. Palma.

A2  Maria Luisa Mangoni
A3 marialuisa.mangoni@uniroma1.it

A4 ¹ Padova Unit, CNR, Institute of Biomolecular Chemistry, Via Marzolo 1, 35131 Padova, Italy

A5
A6 ² Department of Biochemical Sciences, Istituto Pasteur-Fondazione Cenci Bolognetti, Sapienza University of Rome, Via degli Apuli, 9, 00185 Rome, ITALY



2012; Hemshekhar et al. 2016) which have led to the more appropriate designation of “host-defence peptides” (Hancock et al. 2016; Mansour et al. 2014). More specifically, amphibian skin dermal glands, controlled by sympathetic nerves, are among the richest sources of biologically active peptides with pharmacological and antimicrobial activities (Chen et al. 2003; Conlon 2011; Erspamer 1971; Haslam et al. 2014; Konig et al. 2014; Mangoni et al. 2015). They are stored within granules and released on the skin surface by a holocrine mechanism, upon alarm or physical injury (Mangoni et al. 2001, 2007). Each frog species produces its own unique set of AMPs encompassing families of 2–100 closely related members (Mangoni 2006). Esculentins-1 are a class of frog skin AMPs, characterized by a 46 amino acids primary structure and a broad range of antimicrobial activity (Gamberi et al. 2007; Mangoni et al. 2003; Ponti et al. 2003; Simmaco et al. 1994). Studies on their mode of action pointed out the bacterial membrane as the major target. Esculentins-1 possess features common to most linear AMPs, i.e., an overall positive charge at neutral pH and a considerable proportion of hydrophobic residues (Simmaco et al. 1994). These properties are instrumental in allowing an electrostatic interaction between the cationic AMP and the negatively charged components of the microbial cell surface followed by the peptide’s folding into an amphiphilic structure, with a resulting perturbation of the cell membrane permeability and hence cell death (Ganz and Lehrer 1998; Haney et al. 2010; Lohner and Blondelle 2005; Shai 2002). Importantly, in contrast with the conventional antibiotics that interfere with biological events by processes involving specific recognition of chiral targets (Bai et al. 2011; Levy 2002; Savjani et al. 2009), the mechanism of action underlying the killing activity of AMPs is generally based on the physical disruption of the target cell membrane, thus limiting the induction of microbial resistance (Hancock and Rozek 2002; Lohner 2016). Indeed, to become resistant to AMPs, microbes should drastically change the composition of their membrane, an event that could not be achieved without causing a significant harm to the microorganism itself (Mangoni 2006; Mangoni and Shai 2011). It is worth recalling that the membrane of mammalian cells is much richer in zwitterionic phospholipids as compared with that of microbial cells and this difference is one of the major reasons accounting for the preferential activity of AMPs towards bacterial and fungal cells (Epand and Vogel 1999).

The previous studies reported that the N-terminal derivative of esculentin-1a, Esc-1a(1–21)NH₂, [Esc(1–21)] corresponding to its first 20 amino acids followed by an amidated Gly residue (H-Gly-Ile-Phe-Ser-Lys-Leu-Ala-Gly-Lys-Lys-Ile-Lys-Asn-Leu-Leu-Ile-Ser-Gly-Leu-Lys-Gly-NH₂) adopts an alpha-helical conformation in a membrane-mimicking environment and retains the antimicrobial

activity of the full-length peptide esculentin-1a (Gamberi et al. 2007; Ghosh et al. 2016). More recently, Esc(1–21) was shown to display a fast membranolytic activity against both planktonic and biofilm forms of the multi-drug resistant (MDR) opportunistic Gram-negative bacterium *Pseudomonas aeruginosa* (Breidenstein et al. 2011; Drenkard and Ausubel 2002; Kolar et al. 2015; Luca et al. 2013; Uccelletti et al. 2010). This bacterium has the ability to colonize both inert surfaces (such as those of medical devices, e.g., contact lenses) and biological tissues, forming biofilm communities (Hoiby et al. 2011; Parsek and Tolker-Nielsen 2008; Rybtke et al. 2015) which can easily lead to acute and chronic infections, including otitis, pneumonia, and keratitis (Abbouda et al. 2014; Bodey et al. 1983). However, a lower efficacy has been shown by Esc(1–21) against Gram-positive bacteria (Kolar et al. 2015).

In this connection, with the aim of enlarging the spectrum of activity of Esc(1–21) especially against Gram-positive bacteria as well as its biostability to proteases, we explored the effects of the incorporation of α -aminoisobutyric acid (Aib) residues into the peptide sequence. When inserted into the primary structure of peptides, this strongly helicogenic, non-coded, C α -tetrasubstituted α -amino acid is expected to increase the α -helical content of the molecule (Karle and Bala 1990; Toniolo et al. 2001) and potentially confers it a higher resistance against enzymatic degradation (De Zotti et al. 2009, 2012; Yamaguchi et al. 2003). Furthermore, it was previously demonstrated that a stabilized α -helical structure is an essential requirement to enhance the microbicidal activity of a peptide against Gram-positive bacteria and fungi (Giangaspero et al. 2001). In this work, we report on the synthesis of an analog of Esc(1–21), bearing three Aib residues at sequence position 1, 10, and 18 [(Aib^{1,10,18})-Esc(1–21)]; its structural characterization in different environments, by circular dichroism (CD) and two-dimensional nuclear magnetic resonance spectroscopies (2D-NMR) techniques, as well as its biological activity, and compared these results with those of the parent peptide Esc(1–21).

Materials and methods

Materials

Fmoc-amino acids were supplied from Novabiochem (Merck Biosciences, La Jolla, CA, USA), and all other amino-acid derivatives and reagents for peptide synthesis were purchased from Sigma-Aldrich (St. Louis, MO, USA). 1-[Bis(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxide hexafluorophosphate (HATU) was purchased from GLS (Shanghai, China). Trypsin-EDTA was purchased from Invitrogen (Life-Technologies Europe,

167 Monza, Italy); 3(4,5-dimethylthiazol-2yl)2,5-diphenyltetra-
 168 zolium bromide (MTT) was from Sigma-Aldrich (St. Luis,
 169 MO). Dulbecco's modified Eagle's medium (DMEM),
 170 heat-inactivated fetal bovine serum (FBS), glutamine, gen-
 171 tamycin, and penicillin/streptomycin were from Euroclone
 172 (Milan, Italy). Esc(1–21) was purchased from Selleck
 173 Chemicals (Houston, TX, USA) and purified according to
 174 (Di Grazia et al. 2015a, b).

175 Synthesis of [Aib^{1,10,18}]-Esc (1–21)

176 Assembly of the peptide on the Advanced ChemTech
 177 (Louisville, KY, USA) 348 Ω peptide synthesizer was per-
 178 formed on a 0.06-mmol scale by the FastMoc methodology
 179 [HBTU, HOBt, DIEA, single acylation protocol, 45 min
 180 coupling time, *N,N*-dimethylformamide (DMF) as the sol-
 181 vent], starting with Rink Amide MBHA resin (Iris Biotech,
 182 Marktredwitz, Germany) (95 mg, loading 0.65 mmol g⁻¹).
 183 The deprotection of the Fmoc group was performed with
 184 a 20 % piperidine solution in DMF in two steps of 5 and
 185 15 min, respectively. The coupling steps involving Aib
 186 residues, carried out in presence of HATU, were repeated
 187 twice. Boc and *t*Bu side-chain protections were used for
 188 Lys and Ser residues, respectively. Cleavage of the peptide
 189 from the resin, concomitantly with side-chain deprotec-
 190 tions, was achieved by treatment with trifluoroacetic acid
 191 (TFA)/triisopropylsilane (TIS)/water (95:2.5:2.5 v/v). The
 192 crude peptide was purified by reverse-phase flash chroma-
 193 tography using a Biotage Isolera Prime (Uppsala, Sweden)
 194 purification system. The chromatographically homogene-
 195 ous, final peptide was characterized by electrospray ioniza-
 196 tion mass spectrometry (ESI-MS) and NMR.

197 Microorganisms

198 The microorganisms used for the antimicrobial assays were
 199 the reference Gram-negative bacteria *Acinetobacter bau-
 200 mannii* ATCC 19606, *Escherichia coli* D21, *E. coli* ATCC
 201 25922; *Pseudomonas aeruginosa* ATCC 27853, *Yersinia*
 202 *pseudotuberculosis* YPIII, and the Gram-positive bacteria
 203 *Bacillus megaterium* Bm11, *Staphylococcus epidermidis*
 204 ATCC 12228, as well as the clinical isolates *Staphylococ-
 205 cus aureus* 6938; *Staphylococcus capitis* 1; *Staphylococcus*
 206 *epidermidis* 21; and *Staphylococcus hominis* 1. In addition,
 207 two *Candida* strains were employed: the reference *Candida*
 208 *albicans* ATCC 10231 and *C. guilliermondii* from the frog
 209 natural flora (Mangoni et al. 2001).

210 Antimicrobial assay

211 Susceptibility testing was performed by adapting the
 212 microbroth dilution method outlined by the Clinical and
 213 Laboratory Standards Institute, using sterile 96-well plates

(Falcon NJ, USA). The bacterial growth was aseptically
 214 measured by absorbance at 590 nm with a spectrophotom-
 215 eter (UV-1700 Pharma Spec Shimadzu, Tokyo, Japan). Ali-
 216 quots (50 μl) of bacteria in mid-log phase at a concen-
 217 tration of 2×10^6 colony-forming units (CFU)/mL in culture
 218 medium (Mueller–Hinton, MH) were added to 50 μl of
 219 MH broth containing the peptide in serial twofold dilutions
 220 ranging from 64 to 0.25 μM. Inhibition of microbial growth
 221 was visually observed, after 18-h incubation at 37 °C. Anti-
 222 bacterial activity was expressed as the minimal inhibitory
 223 concentration (MIC), the concentration of peptide causing
 224 100 % inhibition of microbial growth. The same procedure
 225 was followed with yeasts in Winge medium (Valenti et al.
 226 1985) using a final cell concentration of 3.5×10^4 CFU/ml
 227 and an incubation time of 18 h at 30 °C.

228 Cell cultures

229 The human type II alveolar epithelial cell line A549 cells
 230 (from the American Type Culture Collection) and the
 231 human immortalized keratinocytes (HaCaT) cell line
 232 were employed. Cells were cultured in DMEM containing
 233 10 % heat-inactivated fetal bovine serum (FBS) and sup-
 234 plemented with L-glutamine (2 mM or 4 mM for A549 or
 235 HaCaT cells, respectively) and antibiotics (0.1 mg/ml of
 236 penicillin and streptomycin for A549 cells; 0.05 mg/ml
 237 of gentamicin for HaCaT cells) at 37 °C and 5 % CO₂ in
 238 25-cm² flasks.

239 Peptides' effect on cell viability

240 The effect of both peptides on the viability of mamma-
 241 lian cells was determined by the inhibition of MTT reduc-
 242 tion to insoluble formazan, by mitochondrial reductases.
 243 Cells suspended in the corresponding culture medium sup-
 244 plemented with glutamine and 2 % FBS without antibiot-
 245 ics were plated in triplicate wells of a microtiter plate, at
 246 4×10^4 cells/well. After overnight incubation at 37 °C in a
 247 5 % CO₂ atmosphere, the medium was replaced with 100-
 248 μl fresh serum-free medium containing the peptides at dif-
 249 ferent concentrations. The plate was incubated for 2 h or
 250 24 h at 37 °C in a 5 % CO₂ atmosphere (Paiva et al. 2012).
 251 Then, the culture medium was removed and replaced with
 252 Hank's buffer (136-mM NaCl; 4.2-mM Na₂HPO₄; 4.4-mM
 253 KH₂PO₄; 5.4-mM KCl; 4.1-mM NaHCO₃, pH 7.2, sup-
 254 plemented with 20-mM D-glucose) containing 0.5 mg/ml MTT.
 255 After 4 h incubation, the formazan crystals were dissolved
 256 by adding 100 μl of acidified isopropanol and viability was
 257 determined by absorbance measurements at 570 nm using
 258 a microplate reader (Infinite M200; Tecan, Salzburg, Aus-
 259 tria). Cell viability was calculated with respect to the control
 260 (cells not treated with peptide). The percentage of viable
 261 cells was calculated according to the formula:



263
$$\frac{(\text{Absorbance sample} - \text{Absorbance blank})}{(\text{Absorbance control} - \text{Absorbance blank})} \times 100,$$

264 where the blank is given by samples without cells and not
265 treated with the peptide.

266 Circular dichroism spectroscopy

267 The CD spectra were measured on a Jasco (Hachioji City, Japan) model J-715 spectropolarimeter equipped with a
268 Haake thermostat (Thermo Fisher Scientific, Waltham, MA, USA). Milli-Q grade water, spectrograde methanol,
269 and TFE (Acros Organic, Geel, Belgium) were used as
270 solvents. Peptide concentrations were determined by UV
271 absorption at 254 nm. For each spectrum, a total of eight
272 scans were averaged. Baselines were corrected by subtracting
273 the solvent contribution. Fused quartz cell of 0.1-mm
274 path length (Hellma, Mühlheim, Germany) was used. For
275 the experiments carried out in mixed solvents, the proper
276 ratio of the individual solutions at the same concentration
277 was mixed. The values are expressed in terms of $[\theta]_T$, the
278 total molar ellipticity (deg \times cm 2 \times dmol $^{-1}$).

281 Nuclear magnetic resonance spectrometry

282 Samples for NMR spectrometry were dissolved in TFE-
283 d₂ solution (peptide concentrations: about 1 and 1.5 mM,
284 respectively, for Esc(1–21) and its Aib^{1,10,18} analog. The
285 spectra were recorded at 298 K. All NMR experiments
286 were performed on a Bruker Avance DMX-600 spectrometer
287 using the TOPSPIN 1.3 software package. Presaturation
288 of the H₂O signal was obtained using a WATERGATE gra-
289 dient program. All homonuclear spectra were acquired by
290 collecting 512 experiments, each one consisting of 64–80
291 scans and 2 K data points. The spin systems of the pro-
292 tein amino-acid residues were identified using the stand-
293 ard DQF-COSY (Rance et al. 1983) and CLEAN-TOCSY
294 (Bax and Davis 1985; Griesinger et al. 1988) spectra. In
295 the latter case, the spin-lock pulse sequence was 70-ms
296 long. NOESY experiments were used for sequence-specific
297 assignment (Wüthrich 1986), the mixing time used was
298 150 ms to avoid spin-diffusion problems.

299 Statistical analysis


300 Data were collected from three independent experiments.
301 Quantitative data are expressed as the mean \pm SEM. Statis-
302 tical analysis was performed using the two-way analysis of
303 variance (ANOVA), with the PRISM software (GraphPad,
304 San Diego, CA, USA). Differences were considered to be
305 statistically significant for $p < 0.05$. The levels of statistical
306 significance are indicated in the legend to figures.

Results and discussion

Synthesis

We synthesized an analog of Esc(1–21) in which we inserted three Aib residues at positions 1, 10, and 18. The choice of the sequence positions of Esc(1–21) to be replaced by Aib was based on the following considerations: (1) the placement of a non-coded Aib residue at position 1 might prevent proteolytic degradation by aminopeptidases, whereas an amidated peptide C-terminus is known to confer protection against carboxypeptidases (Rink et al. 2010; Veber and Freidinger 1985), thus suggesting that the presence of a C-terminal Aib would not be necessary. Concerning the protection by endopeptidases, the introduction of a few additional Aib replacements, possibly quite evenly distributed along the primary structure, is expected to be (at least to some extent) beneficial. (2) The helix-promoting capabilities of Aib are more effective when this residue is placed *internal* to the peptide sequence, where it can display its influence on both the preceding and the following residues in the primary sequence. (3) A helical wheel plot of the primary structure of Esc(1–21), where residues are arranged according to an ideal α -helical folding, is shown in Fig. 1a. In this putative fully α -helical conformation, two faces can be identified, one possessing a more pronounced hydrophobic character and the other a more hydrophilic one. However, strongly hydrophobic residues, such as Ile2, Leu6, and Ile16, are located on the same face occupied by the five charged Lys residues. (4) It is worth recalling that in naturally occurring Aib-rich amphipathic helical peptides of fungal origin known as peptaibiotics (Toniolo and Brückner 2009), the Aib residues are, in general, located within the hydrophobic face but also at its boundary with the hydrophilic one. The most striking example of this latter disposition is provided by the lipopeptide trichogin (Toniolo et al. 1994). All together, these observations suggested us to place three Aib residues in the Esc(1–21) sequence; two of them at positions 1 and 18 (both as a replacement for Gly), and one in substitution for Lys¹⁰, i.e., at the boundary between the hydrophilic and hydrophobic faces (Fig. 1b). As a result of this latter replacement, the overall net charge decreases by one unit if compared with that of the parent peptide, and the overall hydrophilic/hydrophobic profile becomes slightly modified. We principally preferred to give priority to the increase of the helical propensity and proteolytic stability of the central part of the sequence expected as a result of the Lys¹⁰ \rightarrow Aib¹⁰ substitution, even if accompanied by the potentially unfavorable effects outlined above. For the solid-phase peptide synthesis of [Aib^{1,10,18}]-Esc (1–21), we exploited a well-established protocol concerning the use of a strong activating

Fig. 1 Helical wheel plots of the primary structure of Esc(1–21) (a) and its [Aib^{1,10,18}]-analog (b)



357 agent, HATU, in the coupling reactions involving Aib residues
 358 (De Zotti et al. 2012). The synthesis was performed
 359 on a Rink amide MBHA resin using an Fmoc N^α protec-
 360 tion protocol as described in “Materials and methods”. The
 361 cleavage of the peptide from the resin was achieved using a
 362 mixture of TFA/TIS/H₂O. The crude peptide was obtained
 363 in 80 % yield with a purity of 85 %, as evidenced by RP-
 364 HPLC. Reverse-phase flash chromatography allowed the
 365 isolation of the peptide with 97 % purity.

366 H-Aib¹-Ile-Phe-Ser-Lys-Leu-Ala-Gly-Lys-Aib¹⁰-Ile-Lys-Asn-Leu-
 367 Leu-Ile-Ser-Aib¹⁸-Leu-Lys-Gly-NH₂

	MW (calcd for C ₁₀₄ H ₁₈₅ N ₂₇ O ₂₄)	MW (experimental)	t _r (min)	Purity
[Aib ^{1,10,18}]- Esc(1–21)	2196.41	2196.40	9.38 ^a	97 %

368 ^a Elution conditions: Jupiter C18 column, 300 Å, 5 µm; 30–60 % B
 369 in 20 min (A: 9:1 water/acetonitrile, 0.05 % TFA; B: 9:1 acetonitrile/
 370 water, 0.05 % TFA)

372 Antimicrobial activity

373 The activity of [Aib^{1,10,18}]-Esc(1–21) against different
 374 microorganisms, including Gram-negative, Gram-positive
 375 bacteria, and yeasts, was tested by the microdilution broth
 376 assay to determine the MIC. In comparison with the parent
 377 peptide, the incorporation of Aib residues sharply increases
 378 the activity of the peptide against Gram-positive bacte-
 379 ria, as shown by its lower MICs in Table 1. More specifi-
 380 cally, the MIC of the analog carrying Aib residues is eight-
 381 fold lower against *S. epidermidis* strains or 16-fold lower
 382 against *S. capitis* 1. Furthermore, the antibacterial activity
 383 of [Aib^{1,10,18}]-Esc(1–21) becomes even stronger against *S.*
 384 *aureus*, with a 32-fold lower MIC than that of Esc(1–21).
 385 Interestingly, in line with what previously found for the
 386 de novo designed P19 peptide (Giangaspero et al. 2001),

Table 1 Antimicrobial activity of Esc(1–21) and [Aib^{1,10,18}]-Esc(1–21)

Microorganisms	MIC (µM)	
	Esc(1–21)	[Aib ^{1,10,18}]-Esc(1–21)
Gram-negative bacteria		
<i>Acinetobacter baumannii</i> ATCC 19606	2	2
<i>Escherichia coli</i> ATCC 25922	4	2
<i>Escherichia coli</i> D21	2	2
<i>Pseudomonas aeruginosa</i> ATCC 27853	4	4
<i>Yersinia pseudotuberculosis</i> YPIII	1	1
Gram-positive bacteria		
<i>Bacillus megaterium</i> Bm11	2	0.5
<i>Staphylococcus aureus</i> 6938	64	2
<i>Staphylococcus capitis</i> 1	64	4
<i>Staphylococcus epidermidis</i> ATCC 12228	16	2
<i>Staphylococcus epidermidis</i> 21	16	2
<i>Staphylococcus hominis</i> 1	1	1
Yeasts		
<i>Candida albicans</i> ATCC 10231	4	2
<i>Candida guilliermondii</i>	1	1

^a Values are those obtained from at least three of four independent experiments

387 the presence of Aib residues within the peptide sequence
 388 does not significantly affect the activity of the peptide
 389 against Gram-negative bacteria, as indicated by the same
 390 MIC values to those of the parent peptide (Table 1), with
 391 the exception of *E. coli* ATCC 25922 towards which
 392 the analog results to be only twice as powerful as Esc(1–21).
 393 In addition, the anti-yeast activity is not significantly influ-
 394 enced by the presence of Aib residues, and the MIC against



395 *Candida* strains is equal or twofold lower than that of
 396 Esc(1–21). It is very well known that the cell selectivity of
 397 AMPs is governed by several biophysical and biochemical
 398 factors, including not only the peptide's cationicity, amphiphaticity,
 399 hydrophobicity, chain length, helicity, and oligo-
 400 meric state, but also the properties of the target cell surface
 401 (Glukhov et al. 2005; Matsuzaki 2009). In the last 15 years,
 402 several studies reported that an amphipathic structure is
 403 a primary requirement for AMPs to be able to kill Gram-
 404 positive bacteria and fungi, while Gram-negative bacteria
 405 remain susceptible to both non-helical and scrambled pep-
 406 tides (Dathe et al. 1996, 1997; Giangaspero et al. 2001).
 407 However, it is not easy to provide an unequivocal explana-
 408 tion for the difference in the activity profile of Esc(1–21)
 409 and its Aib-containing analog against the three classes of
 410 microorganisms. The different lipid composition existing
 411 between the membrane of Gram-positive and Gram-nega-
 412 tive bacteria or fungi certainly plays a crucial role in deter-
 413 mining the feasibility of the peptide's insertion into the
 414 hydrophobic core of the phospholipid bilayer, which results
 415 in membrane destabilization/perturbation and microbial
 416 death (Epand et al. 2007; Epand and Vogel 1999). In addition,
 417 differences in the cell wall architecture of the target
 418 microorganism would contribute to variations in the pep-
 419 tides' antimicrobial efficacy. Indeed, before reaching the
 420 target, cytoplasmic membrane AMPs need to interact with
 421 lipopolysaccharides of the outer membrane that surrounds
 422 the cell wall in Gram-negative bacteria (Bhunia et al. 2009,
 423 2010; Domadia et al. 2010). Differently, a thicker pepti-
 424 doglycan or a glucan-rich layer is present in the cell wall
 425 of Gram-positive bacteria or fungi, respectively (Free 2013;
 426 Schaffer and Messner 2005). Presumably, according to the
 427 previous studies (Giangaspero et al. 2001), more stringent
 428 structural requirements of a peptide may favor its translo-
 429 cation through the peptidoglycan barrier of Gram-positive
 430 bacteria into the cytoplasmic membrane. This observation
 431 may at least in part justify the lower MIC values found for
 432 the more helical [Aib^{1,10,18}]-Esc(1–21) compared with the
 433 parent Esc(1–21) against these bacterial strains.

434 Peptides' effect on viability of mammalian cell lines

435 The effect of Aib introduction within the primary struc-
 436 ture of Esc(1–21) on the viability of eukaryotic cells was
 437 studied by the MTT assay on different types of mamma-
 438 lian epithelial cell lines: the human alveolar lung epithelial
 439 A549 cells and the human keratinocyte HaCaT cells. As
 440 reported in Fig. 2a, viability of A549 cells after exposure
 441 to [Aib^{1,10,18}]-Esc(1–21) at concentrations 2–4 μM is not
 442 significantly reduced and there is no significant difference
 443 between the two peptides.

444 Similarly, when [Aib^{1,10,18}]-Esc(1–21) is analyzed
 445 against HaCaT cells (Fig. 2b), any marked reduction in the

446 number of metabolically active cells is obtained within the
 447 peptide concentrations of 2–4 μM compared with the harm-
 448 less parent peptide. These findings suggest that [Aib^{1,10,18}]-
 449 Esc(1–21) is not toxic to mammalian cells when used at
 450 its growth inhibitory concentrations against Gram-positive
 451 bacteria (Table 1). Note, however, that when the Aib-con-
 452 taining analog is tested at higher concentrations, i.e., 16,
 453 32, and 64 μM, against A549 cells, cell viability decreases
 454 to ~60, 20, and 5 %, respectively (Fig. 2a) or even further
 455 when the peptide is assayed against keratinocytes (Fig. 2b).
 456 As reported in Fig. 2c and d, the cytotoxicity of [Aib^{1,10,18}]-
 457 Esc(1–21) is only slightly increased after a long-term pep-
 458 tide treatment (24 h), indicating that an irreversible damage
 459 has been caused to the cells.

460 Note that the higher cytotoxicity of the more helical
 461 Aib-containing Esc(1–21) is in agreement with the previ-
 462 ous findings showing that the ease of α-helix formation and
 463 stability are important factors for the mammalian mem-
 464 brane perturbation and cell lysis (Gazit et al. 1994; Pouny
 465 et al. 1992; Shai and Oren 1996; Strahilevitz et al. 1994).

466 Circular dichroism

467 Far-UV CD spectra of Esc(1–21) and its (Aib^{1,10,18}) analog
 468 were acquired in three different solvents: water, TFE, and
 469 100-mM sodium dodecyl sulfate (SDS) aqueous solution
 470 (Fig. 3a, b). In water, both peptides exhibit a random coilAQ4 10
 471 structure, while in TFE and micellar SDS aqueous solu-
 472 tion, they adopt an overall helical conformation. In both
 473 membrane-mimicking environments, each spectrum shows
 474 two negative maxima near 205 and 222 nm and one pos-
 475 itive maximum at 195 nm, indicative of a right-handed heli-
 476 cal conformation for both peptides (Beychock 1967). The
 477 ellipticity ratio $R = [\theta]_{222}/[\theta]_{205}$ calculated in TFE and SDS
 478 solution evidenced a predominant α-helical conformation
 479 for both analogs (Mangoni and Shai 2011).

	R_{SDS}	R_{TFE}
Esc(1–21)	0.76	0.76
[Aib ^{1,10,18}]-Esc(1–21)	0.92	0.75

480 The CD results outlined above would seem to suggest
 481 that the two compounds are conformationally similar. How-
 482 ever, a significant difference emerges from the analysis of
 483 the CD spectra collected in water/TFE mixtures of varying
 484 composition (Fig. 3c, d). Indeed, for each peptide, the set of
 485 spectra is characterized by an isodichroic point at 203 nm,
 486 consistent with a two-state transition from the unordered
 487 conformation in water to the helical structure in 100 %
 488 TFE. The helical content of Esc(1–21) increases sharply
 489 with increasing TFE percentage from 20 to 50 % and to
 490 a lower extent from 50 to 100 % TFE (Fig. 3c), whereas
 491 the Aib-containing analog appears to be much more helical






Fig. 2 Peptides' effect on the viability of A549 cells (**a, c**) or HaCaT cells (**b, d**). Cells were plated in wells of a microtiter plate, at 4×10^4 cells/well in culture medium, as described in the Experimental section. After overnight incubation at 37°C in a 5 % CO_2 atmosphere, the medium was replaced with 100- μl fresh medium supplemented with the peptides at different concentrations. After 2 h (**a, b**) or 24 h (**c, d**) of peptide treatment, cell viability was determined by the MTT

reduction to insoluble formazan. Cell viability is expressed as percentage with respect to the control (cells not treated with the peptide). Data points represent the mean of triplicate samples \pm SEM. The data of the wild-type peptide Esc(1–21) on HaCaT cells were taken from our previous work (Di Grazia et al. 2015a). The levels of statistical significance between the two peptides are: *** $p < 0.001$; **** $p < 0.0001$

than the parent peptide already at 20 % TFE, and its CD spectra vary little at higher TFE percentages (Fig. 3d).

495 Nuclear magnetic resonance analysis

496 The 2D-NMR spectra of Esc(1–21) and its (Aib^{1,10,18})
497 analog were recorded in TFE solution. The proton reso-
498 nances were fully assigned following the Wüthrich pro-
499 cedure (Wüthrich 1986).

500 The NOESY spectra in TFE solution of both peptides
501 evidenced the presence of most of $\text{NH}_i-\text{NH}_{i+1}$ sequential
502 cross peaks, indicative of the occurrence of helical struc-
503 ture (Fig. 4), thus confirming the information obtained
504 from CD spectra.

505 The NOESY fingerprint region of Esc(1–21) shows the
506 $\text{C}^{\alpha}\text{H}_i \rightarrow \text{NH}_{i+2}$ and $\text{C}^{\alpha}\text{H}_i \rightarrow \text{NH}_{i+3}$ cross peaks, diagnostic
507 of helical conformation (Fig. 4a), even if a $\text{C}^{\alpha}\text{H}_i \rightarrow \text{NH}_{i+4}$
508 cross peak, characteristic of α -helical structure could be
509 detected only in the Phe³–Ala⁷ segment (although the
510 extensive overlapping of the signals might hamper their
511 detection in other portions of the sequence).

512 The fingerprint region of the NOESY spectrum of the
513 (Aib^{1,10,18}) analog results better resolved (Fig. 4b). A

514 number of connectivities are necessarily missing, because
515 the quaternary Aib residues (at sequence positions 1, 10,
516 and 18) lack the α hydrogen atom. Nevertheless, in addi-
517 tion to the $\text{C}^{\alpha}\text{H}_i \rightarrow \text{NH}_{i+2}$ and $\text{C}^{\alpha}\text{H}_i \rightarrow \text{NH}_{i+3}$ cross peaks
518 (the latter in a larger number if compared to the parent pep-
519 tide), two $\text{C}^{\alpha}\text{H}_i \rightarrow \text{NH}_{i+4}$ are also evident at the level of the
520 Phe³–Ala⁷ and Leu¹⁵–Leu¹⁹ segments.

521 A comparison of the conformationally relevant signa-
522 tures extracted from the NOESY spectra of Esc(1–21) and
523 its (Aib^{1,10,18}) analog is reported in Fig. 5. Overall, in the
524 C-terminal portion of the (Aib^{1,10,18}) analog, the number
525 of connectivities consistent with a helical conformation is
526 more abundant than in the corresponding region of Esc(1–
527 21). Therefore, both peptides are largely helical, but the
528 introduction of Aib residues appears to increase the popula-
529 tion and stability of the helix in the otherwise more flexible
530 C-terminal domain of Esc(1–21).

Conclusions and perspectives

531 In this work, we demonstrated that the increased alpha-
532 helical content of Esc(1–21), obtained by incorporation of







Fig. 3 Far-UV CD spectra of: **a** Esc(1–21) and **b** [Aib^{1,10,18}]-Esc(1–21) in three different environments: water, TFE, and 100 mM SDS solution; **c** Esc(1–21) and **d** [Aib^{1,10,18}]-Esc(1–21) in water, 20 % TFE, 50 % TFE, and 100 % TFE (peptide concentration 1 mM)

534 three non-proteinogenic Aib residues at positions 1, 10, and
 535 18 (as shown by CD and NMR studies) is sufficient to pro-
 536 voke a dramatic increase in the peptide's activity against
 537 Gram-positive bacteria without significantly increasing its

538 toxicity towards epithelial cells at antimicrobial concentra-
 539 tions. This suggests that the Aib designed analog is a better
 540 candidate than the wild-type peptide for the development of
 541 a new drug against Gram-positive bacterial infections, such

Fig. 4 Fingerprint region of the H/H-NOESY spectrum of Esc(1–21) (a) and [Aib^{1,10,18}]-Esc(1–21) (b) (600 MHz, 1.1 and 1.4 mM, respectively, in TFE-d₂ solution, 298 K). The C^αH_i → NH_{i+2} (red), C^αH_i → NH_{i+3} (green), and C^αH_i → NH_{i+4} (blue) cross peaks, diagnostic of helical conformation, are highlighted



542 as those associated with the human skin or the lung (Lee
543 et al. 2015; Soufi and Soufi 2016). Nevertheless, consider-
544 ing the toxicity of this analog at concentrations higher than
545 the MICs, it would also be useful to develop this peptide

546 for further applications, such as those related to the usage
547 of friendly biocides against Gram-positive bacterial com-
548 munities on metal surfaces in marine engineering sys-
549 tems, e.g., pipelines of the offshore oil and gas industry, to






Fig. 5 Summary of the significant interresidue NOESY cross peaks for Esc(1–21) (a) and [Aib^{1,10,18}]-Esc(1–21) (b) in TFE-d₂ solution. Peptide concentration 1.1 and 1.4 mM, respectively

550 prevent substantial corrosion problems and contamination
551 of agricultural lands (Godwin and Akpan 2014; Schwermer
552 et al. 2008).

553 **Acknowledgments** This work was supported by grants from
554 Sapienza Università di Roma and by FILAS Grant Prot. FILAS-
555 RU-2014-1020. This article does not contain any studies with human
AQ5 participants or animals performed by any of the authors.

557 References

558 Abbouda A, Abicca I, Alio JL (2014) Infectious keratitis following corneal crosslinking: a systematic review of reported cases: AQ6 management, visual outcome, and treatment proposed. Semin Ophthalmol
559 561
562 Bai H, Zhou Y, Hou Z, Xue X, Meng J, Luo X (2011) Targeting bacterial RNA polymerase: promises for future antisense antibiotics development. Infect Disord Drug Targets 11:175–187
563
564 Bax A, Davis DG (1985) MLEV-17-based two dimensional homonuclear magnetization transfer spectroscopy. J Magn Reson 65:355–360
565
566 Beychock S (1967) Circular dichroism of poly- α -amino acids and proteins. In: Fasman GD (ed) Poly- α -amino acids: protein models for conformational studies. Dekker, New York, pp 293–337
567
568
569
570

Bhunia A, Ramamoorthy A, Bhattacharjya S (2009) Helical hairpin structure of a potent antimicrobial peptide MSI-594 in lipopolysaccharide micelles by NMR spectroscopy. Chemistry 15:2036–2040
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598

Bhunia A, Domadia PN, Torres J, Hallock KJ, Ramamoorthy A, Bhattacharjya S (2010) NMR structure of pardaxin, a pore-forming antimicrobial peptide, in lipopolysaccharide micelles: mechanism of outer membrane permeabilization. J Biol Chem 285:3883–3895
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598

Bodey GP, Bolivar R, Feinstein V, Jadeja L (1983) Infections caused by *Pseudomonas aeruginosa*. Rev Infect Dis 5:279–313
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598

Breidenstein EB, de la Fuente-Nunez C, Hancock RE (2011) *Pseudomonas aeruginosa*: all roads lead to resistance. Trends Microbiol 19:419–426
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598

Chen T, Farragher S, Bjourson AJ, Orr DF, Rao P, Shaw C (2003) Granular gland transcriptomes in stimulated amphibian skin secretions. Biochem J 371:125–130
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598

Choi KY, Chow LN, Mookherjee N (2012) Cationic host defence peptides: multifaceted role in immune modulation and inflammation. J Innate Immun 4:361–370
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598

Conlon JM (2011) Structural diversity and species distribution of host-defense peptides in frog skin secretions. Cell Mol Life Sci 68:2303–2315
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598

Dathe M, Wieprecht T, Nikolenko H, Handel L, Maloy WL, MacDonald DL, Beyermann M, Bienert M (1997) Hydrophobicity, hydrophobic moment and angle subtended by charged residues modulate antibacterial and haemolytic activity of amphipathic helical peptides. FEBS Lett 403:208–212
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598



599 Dathe M, Schumann M, Wieprecht T, Winkler A, Beyermann M,
600 Krause E, Matsuzaki K, Murase O, Bienert M (1996) Peptide
601 helicity and membrane surface charge modulate the balance of
602 electrostatic and hydrophobic interactions with lipid bilayers and
603 biological membranes. *Biochemistry* 35:12612–12622

604 De Zotti M, Biondi B, Formaggio F, Toniolo C, Stella L, Park Y,
605 Hahm KS (2009) Trichogin GA IV: an antibacterial and pro-
606 tease-resistant peptide. *J Pept Sci* 15:615–619

607 De Zotti M, Biondi B, Park Y, Hahm KS, Crisma M, Toniolo C, For-
608 maggio F (2012) Antimicrobial lipopeptaibol trichogin GA IV:
609 role of the three Aib residues on conformation and bioactivity.
610 *Amino Acids* 43:1761–1777

611 Di Grazia A, Cappiello F, Imanishi A, Mastrofrancesco A, Picardo M,
612 Paus R, Mangoni ML (2015a) The frog skin-derived antimicro-
613 bial peptide esculentin-1a(1–21)NH₂ promotes the migration of
614 human HaCaT keratinocytes in an EGF receptor-dependent man-
615 ner: a novel promoter of human skin wound healing? *PLoS One*
616 10:e0128663

617 Di Grazia A, Cappiello F, Cohen H, Casciaro B, Luca V, Pini A, Di
618 YP, Shai Y, Mangoni ML (2015b) D-Amino acids incorporation
619 in the frog skin-derived peptide esculentin-1a(1–21)NH₂ is ben-
620 eficial for its multiple functions. *Amino Acids* 47:2505–2519

621 Domadia PN, Bhunia A, Ramamoorthy A, Bhattacharjya S (2010)
622 Structure, interactions, and antibacterial activities of MSI-594
623 derived mutant peptide MSI-594F5A in lipopolysaccharide
624 micelles: role of the helical hairpin conformation in outer-mem-
625 brane permeabilization. *J Am Chem Soc* 132:18417–18428

626 Drenkard E, Ausubel FM (2002) *Pseudomonas* biofilm formation and
627 antibiotic resistance are linked to phenotypic variation. *Nature*
628 416:740–743

629 Epand RF, Savage PB, Epand RM (2007) Bacterial lipid composi-
630 tion and the antimicrobial efficacy of cationic steroid compounds
631 (Ceragenins). *Biochim Biophys Acta* 1768:2500–2509

632 Epand RM, Vogel HJ (1999) Diversity of antimicrobial peptides and
633 their mechanisms of action. *Biochim Biophys Acta* 1462:11–28

634 Erspamer V (1971) Biogenic amines and active polypeptides of the
635 amphibian skin. *Annu Rev Pharmacol* 11:327–350

636 Free SJ (2013) Fungal cell wall organization and biosynthesis. *Adv
637 Genet* 81:33–82

638 Gamberi T, Cavalieri D, Magherini F, Mangoni ML, De Filippo C,
639 Borro M, Gentile G, Simmaco M, Modesti A (2007) An inte-
640 grated analysis of the effects of Escolentin 1–21 on *Saccharomy-
641 ces cerevisiae*. *Biochim Biophys Acta* 1774:688–700

642 Ganz T, Lehrer RI (1998) Antimicrobial peptides of vertebrates. *Curr
643 Opin Immunol* 10:41–44

644 Gazit E, Lee WJ, Brey PT, Shai Y (1994) Mode of action of the anti-
645 bacterial cecropin B2: a spectrofluorometric study. *Biochemistry*
646 33:10681–10692

647 Ghosh A, Bera S, Shai Y, Mangoni ML, Bhunia A (2016) NMR struc-
648 ture and binding of esculentin-1a (1–21)NH₂ and its diastereomer
649 to lipopolysaccharide: correlation with biological functions.
650 *Biochim Biophys Acta* 1858:800–812

651 Giangaspero A, Sandri L, Tossi A (2001) Amphiphilic alpha helical
652 antimicrobial peptides. *Eur J Biochem* 268:5589–5600

653 Glukhov E, Stark M, Burrows LL, Deber CM (2005) Basis for selec-
654 tivity of cationic antimicrobial peptides for bacterial versus
655 mammalian membranes. *J Biol Chem* 280:33960–33967

656 Godwin U, Akpan MGS (2014) Effects of different concentrations of
657 biocides on biofilm microorganisms in oil pipelines in Irri, Delta
658 State, Nigeria. *Int J Biosci* 4:16

659 Gonzalez-Navajas JM, Corr MP, Raz E (2014) The immediate
660 protective response to microbial challenge. *Eur J Immunol*
661 44:2536–2549

662 Griesinger COG, Wüthrich K, Ernst RR (1988) Clean TOCSY for
663 proton spin system identification in macromolecules. *J Am
664 Chem Soc* 110:7870–7872

665 Hancock RE, Rozek A (2002) Role of membranes in the activi-
666 ties of antimicrobial cationic peptides. *FEMS Microbiol Lett*
667 206:143–149

668 Hancock RE, Haney EF, Gill EE (2016) The immunology of host
669 defence peptides: beyond antimicrobial activity. *Nat Rev Immunol*
670 16:321–334

671 Haney EF, Nathoo S, Vogel HJ, Prenner EJ (2010) Induction of non-
672 lamellar lipid phases by antimicrobial peptides: a potential link
673 to mode of action. *Chem Phys Lipids* 163:82–93

674 Haslam IS, Roubos EW, Mangoni ML, Yoshizato K, Vaudry H,
675 Kloepper JE, Pattwell DM, Maderson PF, Paus R (2014) From
676 frog integument to human skin: dermatological perspectives
677 from frog skin biology. *Biol Rev Camb Philos Soc* 89:618–655

678 Hemshekhar M, Anaparti V, Mookherjee N (2016) Functions of cati-
679 onic host defense peptides in immunity. *Pharmaceuticals* 9(3)

680 Hoiby N, Ciofu O, Johansen HK, Song ZJ, Moser C, Jensen PO,
681 Molin S, Givskov M, Tolker-Nielsen T, Bjarnsholt T (2011) The
682 clinical impact of bacterial biofilms. *Int J Oral Sci* 3:55–65

683 Islas-Rodriguez AE, Marcellini L, Orioni B, Barra D, Stella L, Man-
684 goni ML (2009) Escolentin 1–21: a linear antimicrobial peptide
685 from frog skin with inhibitory effect on bovine mastitis-causing
686 bacteria. *J Pept Sci* 15:607–614

687 Karle IL, Balaram P (1990) Structural characteristics of alpha-heli-
688 cal peptide molecules containing Aib residues. *Biochemistry*
689 29:6747–6756

690 Kolar SS, Luca V, Baidouri H, Mannino G, McDermott AM, Mangoni
691 ML (2015) Escolentin-1a(1–21)NH₂: a frog skin-derived peptide
692 for microbial keratitis. *Cell Mol Life Sci* 72:617–627

693 Konig E, Bininda-Emonds OR, Shaw C (2014) The diversity and evo-
694 lution of anuran skin peptides. *Peptides* 63C:96–117

695 Lee YR, Houngue C, Hall RG (2015) Treatment of community-
696 acquired pneumonia. *Expert Rev Anti Infect Ther* 13:1109–1121

696 Levy SB (2002) The 2000 Garrod lecture. Factors impacting on
697 the problem of antibiotic resistance. *J Antimicrob Chemother*
698 49:25–30

699 Lohner K (2016) Novel antibiotics based upon the multiple mech-
700 anisms of membrane perturbation by antimicrobial peptides. *Curr
701 Top Med Chem (in press)*

702 Lohner K, Blondelle SE (2005) Molecular mechanisms of membrane
703 perturbation by antimicrobial peptides and the use of biophysical
704 studies in the design of novel peptide antibiotics. *Comb Chem
705 High Throughput Screen* 8:241–256

706 Luca V, Stringaro A, Colone M, Pini A, Mangoni ML (2013) Escu-
707 lentin(1–21), an amphibian skin membrane-active peptide with
708 potent activity on both planktonic and biofilm cells of the bac-
709 terial pathogen *Pseudomonas aeruginosa*. *Cell Mol Life Sci*
710 70:2773–2786

711 Mangoni ML (2006) Temporins, anti-infective peptides with expand-
712 ing properties. *Cell Mol Life Sci* 63:1060–1069

713 Mangoni ML, Shai Y (2011) Short native antimicrobial peptides
714 and engineered ultrashort lipopeptides: similarities and differ-
715 ences in cell specificities and modes of action. *Cell Mol Life Sci*
716 68:2267–2280

717 Mangoni ML, Marcellini HG, Simmaco M (2007) Biological char-
718 acterization and modes of action of temporins and bombinins H,
719 multiple forms of short and mildly cationic anti-microbial pep-
720 tides from amphibian skin. *J Pept Sci* 13:603–613

721 Mangoni ML, Luca V, McDermott AM (2015) Fighting microbial
722 infections: A lesson from amphibian skin-derived esculentin-1
723 peptides. *Peptides* 71:286–295

724 Mangoni ML, Miele R, Renda TG, Barra D, Simmaco M (2001) The
725 synthesis of antimicrobial peptides in the skin of *Rana esculenta*
726 is stimulated by microorganisms. *FASEB J* 15:1431–1432

727 Mangoni ML, Fiocco D, Mignogna G, Barra D, Simmaco M
728 (2003) Functional characterisation of the 1–18 fragment of
729



730 esculentin-1b, an antimicrobial peptide from *Rana esculenta*.
731 Peptides 24:1771–1777

732 Manning MC, Woody RW (1991) Theoretical CD studies of polypep-
733 tide helices: examination of important electronic and geometric
734 factors. *Biopolymers* 31:569–586

735 Mansour SC, Pena OM, Hancock RE (2014) Host defense peptides:
736 front-line immunomodulators. *Trends Immunol* 35:443–450

737 Matsuzaki K (2009) Control of cell selectivity of antimicrobial pep-
738 tides. *Biochim Biophys Acta* 1788:1687–1692

739 Mookherjee N, Hancock RE (2007) Cationic host defence peptides:
740 innate immune regulatory peptides as a novel approach for treat-
741 ing infections. *Cell Mol Life Sci* 64:922–933

742 Nicolas P, Mor A (1995) Peptides as weapons against microorganisms
743 in the chemical defense system of vertebrates. *Annu Rev Micro-
744 biol* 49:277–304

745 Paiva AD, de Oliveira MD, de Paula SO, Baracat-Pereira MC, Breu-
746 kink E, Mantovani HC (2012) Toxicity of bovin HC5 against
747 mammalian cell lines and the role of cholesterol in bacteriocin
748 activity. *Microbiology* 158:2851–2858

749 Parsek MR, Tolker-Nielsen T (2008) Pattern formation in *Pseu-*
750 *domonas aeruginosa* biofilms. *Curr Opin Microbiol* 11:560–566

751 Ponti D, Mangoni ML, Mignogna G, Simmaco M, Barra D (2003)
752 An amphibian antimicrobial peptide variant expressed in *Nicotiana tabacum* confers resistance to phytopathogens. *Biochem J*
753 370:121–127

754 Pouy Y, Rapaport D, Mor A, Nicolas P, Shai Y (1992) Interaction of
755 antimicrobial dermaseptin and its fluorescently labeled analogues
756 with phospholipid membranes. *Biochemistry* 31:12416–12423

757 Rance M, Sorensen OW, Bodenhausen G, Wagner G, Ernst RR,
758 Wuthrich K (1983) Improved spectral resolution in cosy 1H
759 NMR spectra of proteins via double quantum filtering. *Biochem
760 Biophys Res Commun* 117:479–485

761 Rink R, Arkema-Meter A, Baudoin I, Post E, Kuipers A, Nelemans
762 SA, Akanbi MH, Moll GN (2010) To protect peptide phar-
763 maceuticals against peptidases. *J Pharmacol Toxicol Methods*
764 61:210–218

765 Rybtke M, Hultqvist LD, Givskov M, Tolker-Nielsen T (2015) *Pseu-*
766 *domonas aeruginosa* Biofilm Infections: Community Structure,
767 Antimicrobial Tolerance and Immune Response. *J Mol Biol*
768 427:3628–3645

769 Savjani JK, Gajjar AK, Savjani KT (2009) Mechanisms of resistance:
770 useful tool to design antibacterial agents for drug-resistant bacteria. *Mini Rev Med Chem* 9:194–205

771 Schaffer C, Messner P (2005) The structure of secondary cell wall
772 polymers: how Gram-positive bacteria stick their cell walls
773 together. *Microbiology* 151:643–651

774

775 Schwermer CU, Lavik G, Abed RM, Dunsmore B, Ferdelman TG,
776 Stoodley P, Gieseke A, de Beer D (2008) Impact of nitrate on the
777 structure and function of bacterial biofilm communities in pipe-
778 lines used for injection of seawater into oil fields. *Appl Environ
779 Microbiol* 74:2841–2851

780 Shai Y (2002) Mode of action of membrane active antimicrobial pep-
781 tides. *Biopolymers* 66:236–248

782 Shai Y, Oren Z (1996) Diastereoisomers of cytolsins, a novel class of
783 potent antibacterial peptides. *J Biol Chem* 271:7305–7308

784 Simmaco M, Mignogna G, Barra D, Bossa F (1994) Antimicrobial
785 peptides from skin secretions of *Rana esculenta*. Molecular cloning
786 of cDNAs encoding esculentin and brevinins and isolation of
787 new active peptides. *J Biol Chem* 269:11956–11961

788 Soufi Y, Soufi B (2016) Mass spectrometry-based bacterial proteomics:
789 focus on dermatologic microbial pathogens. *Front Microbiol*
790 7:181

791 Strahilevitz J, Mor A, Nicolas P, Shai Y (1994) Spectrum of anti-
792 microbial activity and assembly of dermaseptin-b and its
793 precursor form in phospholipid membranes. *Biochemistry*
794 33:10951–10960

795 Toniolo C, Crisma M, Formaggio F, Peggion C (2001) Control of pep-
796 tide conformation by the Thorpe-Ingold effect (C alpha-tetrasub-
797stitution). *Biopolymers* 60:396–419

798 Toniolo C, Peggion C, Crisma M, Formaggio F, Shui X, Eggleston DS
799 (1994) Structure determination of racemic trichogin A IV using
800 centrosymmetric crystals. *Nat Struct Biol* 1:908–914

801 Toniolo C, Brückner H (2009) Peptaibiotics: fungal peptides contain-
802 ing α -dialkyl α -amino Acids. Wiley-VCH and VHCA, Wein-
803 heim/Zürich. *Chem Biochem* 10:2266–2267

804 Uccelletti D, Zanni E, Marcellini L, Palleschi C, Barra D, Mangoni
805 ML (2010) Anti-*Pseudomonas* activity of frog skin antimicro-
806 bial peptides in a *Caenorhabditis elegans* infection model: a
807 plausible mode of action in vitro and in vivo. *Antimicrob Agents
808 Chemother* 54:3853–3860

809 Valenti P, Visca P, Antonini G, Orsi N (1985) Antifungal activi-
810 ty of ovotransferrin towards genus *Candida*. *Mycopathologia*
811 89:169–175

812 Veber DF, Freidinger RM (1985) The design of metabolically-stable
813 peptide analogs. *Trends Neurosci* 8:392–396

814 Wüthrich K (1986) NMR of proteins and nucleic acids. Wiley, New
815 York

816 Yamaguchi H, Kodama H, Osada S, Kato F, Jelokhani-Niaraki M,
817 Kondo M (2003) Effect of alpha, alpha-dialkyl amino acids on
818 the protease resistance of peptides. *Biosci Biotechnol Biochem*
819 67:2269–2272

820



Author Query Form

Please ensure you fill out your response to the queries raised below and return this form along with your corrections

Dear Author

During the process of typesetting your article, the following queries have arisen. Please check your typeset proof carefully against the queries listed below and mark the necessary changes either directly on the proof/online grid or in the 'Author's response' area provided below

Query	Details Required	Author's Response
AQ1	Kindly check and confirm the edit made in the title.	
AQ2	Please check and confirm the order of organisation division and name processed in affiliations and amend if necessary.	
AQ3	Please check and provide indicator for superscript letter 'a' in table body.	
AQ4	Figures 3–5 are poor in quality as its labels are not readable. Please supply a new version of the said figure with legible labels preferably in .eps, .tiff or .jpeg format with 600 dpi resolution.	
AQ5	As conflict of interest statement is mandatory for this journal, please check and provide the same.	
AQ6	Please update Ref. Abbouda et al. (2014) with volume and page range if possible.	
AQ7	References Islas-Rodriguez et al. (2009) and Manning and Woody (1991) were provided in the reference list; however, this was not mentioned or cited in the manuscript. Please provide the location of where to insert the reference citation in the main body text.	